Gilead-Teva Deal Costs To Buyers Top $3.6B As Plaintiffs Rest

By Bonnie Eslinger · June 20, 2023, 9:59 PM EDT

Health care companies and health plans called their final witnesses Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

3:19-cv-02573

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019